Literature DB >> 5321298

Carcinoma in situ of the endometrium.

H Gore, A T Hertig.   

Abstract

Entities:  

Mesh：

Year:  1966        PMID： 5321298     DOI： 10.1016/0002-9378(66)90391-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN： 0002-9378            Impact factor:   8.661


× No keyword cloud information.
  7 in total

1.  PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.

Authors:  Kimberly H Allison; Kristen Upson; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Jennifer Doherty; Elizabeth M Swisher; Rochelle L Garcia
Journal:  Int J Gynecol Pathol       Date:  2012-03       Impact factor: 2.762

2.  [DNA content of normal, hyperplastic and malignant endometrium, determined cytofotometrically (author's transl)].

Authors:  H Sachs; E U wambach; K Würthner
Journal:  Arch Gynakol       Date:  1974

Review 3.  Management of endometrial precancers.

Authors:  Cornelia L Trimble; Michael Method; Mario Leitao; Karen Lu; Olga Ioffe; Moss Hampton; Robert Higgins; Richard Zaino; George L Mutter
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

4.  [The hyperplasia forms of the endometrium and their correlations to the endometrium carcinoma (author's transl)].

Authors:  H Ritzmann; H G Hillemanns
Journal:  Arch Gynakol       Date:  1977-11-29

5.  Diagnosing endometrial hyperplasia: why is it so difficult to agree?

Authors:  Kimberly H Allison; Susan D Reed; Lynda F Voigt; Carolyn D Jordan; Kathryn M Newton; Rochelle L Garcia
Journal:  Am J Surg Pathol       Date:  2008-05       Impact factor: 6.394

Review 6.  Therapeutic options for management of endometrial hyperplasia.

Authors:  Vishal Chandra; Jong Joo Kim; Doris Mangiaracina Benbrook; Anila Dwivedi; Rajani Rai
Journal:  J Gynecol Oncol       Date:  2015-12-01       Impact factor: 4.401

7.  Endometrial Glandular Dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of Type II endometrial cancers.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Diagn Pathol       Date:  2008-02-08       Impact factor: 2.644
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.